INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The objective of this multicentric, randomised, Phase III study is to demonstrate
superiority, in terms of survival, of trabectedin and Pegylated Liposomal Doxorubicin (PLD)
versus carboplatin and PLD in partially-platinum sensitive ovarian cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research